Willem A. De Jongh
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice.
Journal: Vaccine
Published: April 20, 2026
A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25.
Journal: Nature nanotechnology
Published: January 25, 2024
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines.
Journal: Vaccines
Published: November 08, 2022
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Journal: The Lancet. Microbe
Published: September 05, 2022
FAS2FURIOUS: Moderate-Throughput Secreted Expression of Difficult Recombinant Proteins in Drosophila S2 Cells.
Journal: Frontiers in bioengineering and biotechnology
Published: February 09, 2022
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
Journal: mBio
Published: October 12, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Journal: Med (New York, N.Y.)
Published: July 05, 2021
Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes.
Journal: Cellular microbiology
Published: December 20, 2018
First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 17, 2018
Last Updated: 09/26/2026